These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27380219)

  • 21. Antiresorptive treatment-associated ONJ.
    Eleutherakis-Papaiakovou E; Bamias A
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 29063702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.
    Boonyapakorn T; Schirmer I; Reichart PA; Sturm I; Massenkeil G
    Oral Oncol; 2008 Sep; 44(9):857-69. PubMed ID: 18282788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.
    Estilo CL; Van Poznak CH; Wiliams T; Bohle GC; Lwin PT; Zhou Q; Riedel ER; Carlson DL; Schoder H; Farooki A; Fornier M; Halpern JL; Tunick SJ; Huryn JM
    Oncologist; 2008 Aug; 13(8):911-20. PubMed ID: 18695259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-induced osteonecrosis of the jaw: the state of the art.
    Fassio A; Bertoldo F; Idolazzi L; Viapiana O; Rossini M; Gatti D
    Reumatismo; 2017 May; 69(1):9-15. PubMed ID: 28535616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib.
    Bozas G; Roy A; Ramasamy V; Maraveyas A
    Onkologie; 2010; 33(6):321-3. PubMed ID: 20523097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw.
    Musolino C; Oteri G; Allegra A; Mania M; D'Ascola A; Avenoso A; Innao V; Allegra AG; Campo S
    Ann Hematol; 2018 Jul; 97(7):1259-1269. PubMed ID: 29546453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
    O'Ryan FS; Khoury S; Liao W; Han MM; Hui RL; Baer D; Martin D; Liberty D; Lo JC
    J Oral Maxillofac Surg; 2009 Jul; 67(7):1363-72. PubMed ID: 19531404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.
    Sánchez A; Blanco R
    Osteoporos Int; 2017 Mar; 28(3):1145-1147. PubMed ID: 27866217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports.
    Agrillo A; Nastro Siniscalchi E; Facchini A; Filiaci F; Ungari C
    Eur Rev Med Pharmacol Sci; 2012 Jul; 16(7):952-7. PubMed ID: 22953645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer.
    Van Poznak CH; Unger JM; Darke AK; Moinpour C; Bagramian RA; Schubert MM; Hansen LK; Floyd JD; Dakhil SR; Lew DL; Wade JL; Fisch MJ; Henry NL; Hershman DL; Gralow J
    JAMA Oncol; 2021 Feb; 7(2):246-254. PubMed ID: 33331905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04).
    Rathbone EJ; Brown JE; Marshall HC; Collinson M; Liversedge V; Murden GA; Cameron D; Bell R; Spensley S; Agrawal R; Jyothirmayi R; Chakraborti P; Yuille F; Coleman RE
    J Clin Oncol; 2013 Jul; 31(21):2685-91. PubMed ID: 23796998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retrospective Audit: Does Prior Assessment by Oral and Maxillofacial Surgeons Reduce the Risk of Osteonecrosis of The Jaw in Patients Receiving Bone-Targeted Therapies for Metastatic Cancers to the Skeleton?--Part II.
    Turner B; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
    Urol Nurs; 2016; 36(3):117-22, 132. PubMed ID: 27501592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
    Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
    Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An evidence-based review of risk-reductive strategies for osteonecrosis of the jaws among cancer patients.
    Kyrgidis A; Tzellos TG; Toulis K; Arora A; Kouvelas D; Triaridis S
    Curr Clin Pharmacol; 2013 May; 8(2):124-34. PubMed ID: 23092218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients.
    Capalbo S; Delia M; Diomede D; Dargenio M; Chiefa A; Favia G; Liso V
    Int J Hematol; 2006 Jun; 83(5):439-42. PubMed ID: 16787865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.
    Otto S; Schreyer C; Hafner S; Mast G; Ehrenfeld M; Stürzenbaum S; Pautke C
    J Craniomaxillofac Surg; 2012 Jun; 40(4):303-9. PubMed ID: 21676622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study.
    Guillot A; Joly C; Barthélémy P; Meriaux E; Negrier S; Pouessel D; Chevreau C; Mahammedi H; Houede N; Roubaud G; Gravis G; Tartas S; Albiges L; Vassal C; Oriol M; Tinquaut F; Espenel S; Bouleftour W; Culine S; Fizazi K
    Clin Genitourin Cancer; 2019 Feb; 17(1):e38-e43. PubMed ID: 30279115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?
    Pilanci KN; Alco G; Ordu C; Sarsenov D; Celebi F; Erdogan Z; Agacayak F; Ilgun S; Tecimer C; Demir G; Eralp Y; Okkan S; Ozmen V
    Medicine (Baltimore); 2015 May; 94(18):e671. PubMed ID: 25950681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osteonecrosis of the jaw in patients with metastatic breast cancer: ethnic and socio-economic aspects.
    Quispe D; Shi R; Burton G
    Breast J; 2011; 17(5):510-3. PubMed ID: 21762241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.